While TAMs are generally considered as anti-inflammatory M2, characterized by an IL-10high/IL-12low cytokine profile and defective NF-κB activation [27, 136, 137], these cells are also known to contribute to angiogenesis and cancer cell aggressiveness via the secretion of the M1-associated and NF-κB-regulated mediators, such as TNFα, IL-1β, and MMP-9 [138–140]. The gene discussed is NFKB1; the disease is cancer.